Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Purav P Vagadia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Northwestern University, Evanston, Illinois 60208, United States. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
MNK activity is regulated by the p38 and Erk MAPK pathways. Phosphorylation of MNK leads to its activation and binding to the eIF4G/eIF4E complex. MNK then phosphorylates eIF4E at Ser209, whose activation is associated with oncogene translation, leading to tumorigenesis. Given this important role for eIF4E in tumorigenesis, MNK inhibition with novel small molecule inhibitors could be a promising strategy to combat AML, which continues to be an area of unmet medical need. Here, we report the medicinal optimization of a series of novel inhibitors and their evaluation of their effects on eIF4E and leukemia cell viability. We discovered a class of ether-containing compounds with a high MNK1/2 selectivity. These MNK inhibitors show good potency in reducing cell viability and colony formation and have desirable pharmacokinetic properties. X-ray cocrystallization was accomplished to confirm the binding mode of our inhibitors and aid in future optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, United States.
- Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.
- Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612, United States.
- High-Throughput Analysis Laboratory, Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois 60208, United States.
- The Integrated Molecular Structure Education and Research Center (IMSERC), Northwestern University, Evanston, Illinois 60208, United States.
ORCID-Profile: Javier Izquierdo-Ferrer, Elspeth M Beauchamp, Charlotte L Stern, Rama K Mishra, Gary E Schiltz
Förderung
- NCI NIH HHS
- NIH HHS
- NINDS NIH HHS
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- NIH Office of the Director
Zitieren
APA
Vagadia, P. P., Izquierdo-Ferrer, J., Mazewski, C., Blyth, G., Beauchamp, E. M., Clutter, M. R., Stern, C. L., Mishra, R. K., Nahotko, D., Small, S., Eckerdt, F., Platanias, L. C., & Schiltz, G. E. (2025). Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03158
Vancouver
Vagadia PP, Izquierdo-Ferrer J, Mazewski C, Blyth G, Beauchamp EM, Clutter MR, et al. Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03158
BibTeX
@article{Vagadia2025,
author = {Vagadia, Purav P and Izquierdo-Ferrer, Javier and Mazewski, Candice and Blyth, Gavin and Beauchamp, Elspeth M and Clutter, Matthew R and Stern, Charlotte L and Mishra, Rama K and Nahotko, Dominik and Small, Sara and Eckerdt, Frank and Platanias, Leonidas C and Schiltz, Gary E},
title = {Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03158}
}
EUVIMED